-
Product Insights
NewFragile X Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Fragile X Syndrome Clinical Trial Report Overview A total of 110 fragile X syndrome clinical trials were conducted as of March 2024. The fragile X syndrome clinical trial report provides a comprehensive understanding of the fragile X syndrome clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cetuximab Biobetter in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cetuximab Biobetter in Nasopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cetuximab Biobetter in Nasopharyngeal Cancer Drug Details: HLX-07 is under...
-
Product Insights
Seizures – Drugs In Development, 2023
Global Markets Direct’s, ‘Seizures - Drugs In Development, 2023’, provides an overview of the Seizures pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Childhood Epilepsy – Drugs In Development, 2023
Global Markets Direct’s, ‘Childhood Epilepsy - Drugs In Development, 2023’, provides an overview of the Childhood Epilepsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Childhood Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Infantile Spasm (West Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Infantile Spasm (West Syndrome) - Drugs In Development, 2023’, provides an overview of the Infantile Spasm (West Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Infantile Spasm (West Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Status Epilepticus – Drugs In Development, 2023
Global Markets Direct’s, ‘Status Epilepticus - Drugs In Development, 2023’, provides an overview of the Status Epilepticus pipeline landscape. The report provides comprehensive information on the therapeutics under development for Status Epilepticus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Schizophrenia – Drugs In Development, 2023
Global Markets Direct’s, ‘Schizophrenia - Drugs In Development, 2023’, provides an overview of the Schizophrenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Angelman Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Angelman Syndrome - Drugs In Development, 2023’, provides an overview of the Angelman Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Angelman Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Partial Seizure – Drugs In Development, 2023
Global Markets Direct’s, ‘Partial Seizure - Drugs In Development, 2023’, provides an overview of the Partial Seizure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Partial Seizure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Tuberous Sclerosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Tuberous Sclerosis - Drugs In Development, 2023’, provides an overview of the Tuberous Sclerosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tuberous Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...